Research
Hormonal
Semaglutide improved hemoglobin A1c levels and reduced glycemic variability without increasing hypoglycemia.
Semaglutide may enhance glycemic control in type 1 diabetes patients.
StrongSupportsmedium confidence
Despite less insulin, hemoglobin A1c improved, with reduced glycemic variability and no increase in hypoglycemia.
Why this rating
The findings are based on a case study with clear outcomes.
Source
Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
Lisa M. Raven et al. · JCEM Case Reports · 2022
case_studyCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →